RAS pathway alterations have been associated with chemotherapy resistance and inferior outcome in BCP-ALL and the large majority of aberrations (98%) occur in NRAS, KRAS, PTPN11, and FLT3 genes. Here, FLT3 is linked to acute lymphoblastic leukemia.